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Background: A major question when attempting to eradicate and treat HIV-1 infection is how to
reactivate latent proviruses. Stimulating HIV-1-speciﬁc cytolytic T lymphocytes (CTL) has been shown to
facilitate the elimination of the latent viral reservoir after viral reactivation. Regulatory T (Treg) cells are
known to be capable of lowering both HIV-speciﬁc immunoreactions and general immune activation
during HIV-1 infection. It was hypothesized that the depletion of Treg cells could increase the HIV-1-
speciﬁc cytolytic T lymphocyte response and reactivate HIV-1 p24 production.
Methods: Treg cells were isolated by isolation kit according to the surface marker of Treg cells. Real-time
PCR method was used to quantify HIV-1 DNA. P24 antigens in the cell culture supernatant was done by
ELISA. Cells activation and HIV speciﬁc HIV-1 CD8+ T cells were analyses using a FACSCalibur ﬂow
cytometer and CELLQUEST software.
Results: This study included both HIV-infected patients who were antiviral treatment-naı¨ve and patients
with sustained viral responses to antiretroviral therapy (ART) for 1 or 5 years. It was found that the HIV-
DNA levels in Treg cells were approximately 10-fold higher than those in non-Treg CD4+ cells and that
the depletion of Treg cells could enhance the frequency of HIV-1-speciﬁc CTL and immune activation
after 5 years of effective ART.
Conclusions: CD4+CD25+CD127 regulatory cells play multiple roles in maintaining HIV-1 p24
production in long-term ART patients. Treg cells may be a target for eliminating the latent HIV
reservoir after effective long-term ART.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Since the discovery of HIV, many classes of antiviral drugs that
can limit viral replication to an undetectable level have been
developed. These effectively prevent the occurrence of AIDS-
related symptoms in infected individuals. Although current
antiretroviral therapies can control viral replication, the persis-
tence of latent HIV is a major obstacle to eradicating the virus from
an infected individual. In latently infected cells, the integrated* Corresponding authors. Tel.: +86 010 63053963; fax: +86 010 63294417.
E-mail addresses: lihongjun00113@126.com (H.-J. Li), whdoc900@gmail.com
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1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).provirus is transcriptionally silent,1–3 but is able to produce
replication-competent viruses upon activation.4,5 Because of the
persistence of a viral reservoir,3,6,7 life-long antiretroviral therapy
(ART) is required, which raises concerns about the adverse effects
over decades of therapy, the development of resistance, and the
ﬁnancial burden of long-term treatment. Accordingly, strategies to
eradicate HIV-1 from infected individuals are urgently needed.
Efforts have been focused on the possibility of using pharma-
cological interventions to ‘purge’ latent viruses. However, early
studies using interleukin 2 (IL-2) alone or in combination with
anti-CD3 antibodies to reactivate latent HIV-1 failed to eliminate
the reservoir.1,8–12 Recent studies have focused on identifying
small molecules that are able to reactivate latent virus.13 Two US
Food and Drug Administration (FDA)-approved drugs, valproicciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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reactivate latent virus in primary cell models and in cells from
infected individuals. However, clinical studies of valproic acid,
which possesses histone deacetylase (HDAC) inhibitor activity,
have failed to show a consistent effect in eliminating the latent
reservoir.18–23 Although these data indicate that latent HIV
proviruses can be forced out of transcriptional silencing, evidence
that latently infected resting CD4+ T cells would be killed upon
exposure to reactivating agents is still lacking both in vitro and
in vivo.23,24 Nonetheless, Shan et al. found that the stimulation of
HIV-1-speciﬁc cytotoxic T lymphocyte (CTL) responses prior to
viral reactivation may be essential for eradicating latent viruses.1
CD4+CD25+CD127 regulatory T (Treg) cells have been shown to
play an important role in maintaining immunological tolerance to
both self and foreign antigens by suppressing aggressive T cell
responses.25–28 Several studies have reported that during HIV
infection, Treg cells contribute to HIV-speciﬁc immune dysfunction
by limiting HIV-speciﬁc immunoreaction,29–31 and other studies
have indicated that Treg cells reduce immune activation.25,32,33
The majority of studies involving patients who were HIV-infected
long-term non-progressors (LTNPs) or elite controllers, have
reported decreased Treg cell percentages in peripheral blood34–37
and rectal mucosa37 compared with regular progressors.
Treg cells are susceptible to HIV infection both in vitro38–41 and
in vivo.42,43 Of note, it has been reported that HIV-DNA-harboring
cells appear to be more abundant in Treg cells than in non-Treg
cells in patients on prolonged ART.44 Similar results have been
found in the mucosa of simian immunodeﬁciency virus (SIV)-
infected macaques.25,45 These data suggest that Treg cells
constitute a part of the viral reservoir.
It is important to determine whether the depletion of Treg cells
would assist in the eradication of HIV-1 production. It was
hypothesized that the depletion of Treg cells would contribute to
elevating the frequency of HIV-speciﬁc CTL and HIV-1 production,
which may beneﬁt latent viral eradication in patients on prolongedTable 1
Characteristics of patients in this study
Patient Age (years) Gender CD4 before ART (cells/ml) CD4 after 
1 38 M 50 - 
2 28 M 259 - 
3 41 M 225 - 
4 30 M 226 - 
5 29 M 271 - 
6 30 M 267 - 
7 28 M 202 - 
8 43 M 153 - 
9 50 M 256 - 
10 49 M 260 - 
11 28 M 136 312 
12 28 F 304 348 
13 24 M 321 373 
14 26 M 227 295 
15 29 F 327 386 
16 35 M 334 476 
17 25 M 236 327 
18 32 M 198 218 
19 33 F 245 302 
20 26 F 221 261 
21 43 M 113 350 
22 27 M 313 720 
23 24 M 238 430 
24 26 M 211 398 
25 30 M 176 389 
26 27 F 220 410 
27 25 F 257 415 
28 24 M 224 409 
29 37 M 173 379 
30 36 M 106 350 
ART, antiretroviral therapy; M, male; F, female.ART. To assess this hypothesis, treatment-naı¨ve HIV-infected
patients and HIV-infected patients who had received ART for 1 or
5 years with sustained viral responses were studied. It was found
that Treg cells constitute an important factor in HIV-1 p24
production and that the depletion of Treg cells enhanced the
frequency of HIV-1-speciﬁc CTL, immune activation, and the
depletion of p24 expression after 5 years of effective ART
treatment.
2. Materials and methods
2.1. Patients
Thirty adults who were chronically infected with HIV-1 (cared
for by the Center for Infectious Diseases, Beijing You’an Hospital,
Capital Medical University) were enrolled in this study. No
enrolled patient was co-infected with hepatitis B virus (HBV) or
hepatitis C virus (HCV). The patients were divided into three
groups: 10 AIDS patients who were ART-naı¨ve (Table 1), 10 patients
who had received ART for 1 year (ART1) and who exhibited
persistent viral suppression with plasma HIV-1 RNA levels below
50 copies/ml after 12 weeks of ART (Table 1), and 10 patients who
had received ART for 5 years (ART5) and who exhibited persistent
viral suppression with plasma HIV-1 RNA levels below 50 copies/
ml after 12 weeks of ART (Table 1). The ART regimen included two
nucleoside reverse-transcriptase inhibitors (NRTIs) plus one non-
nucleoside reverse-transcriptase inhibitor (NNRTI). CD4+ T cell
numbers were <200 cells/ml before ART treatment for the ART-
treatment patients.
The exclusion criteria included pregnancy, active tuberculosis
(TB; deﬁned as suspected TB or being in the ﬁrst 2 months of anti-
TB therapy), and moribund status.32 The study protocol was
approved by the Beijing You’an Ethics Committee, and written
informed consent was obtained from each subject. All of the HIV-
infected subjects were serologically identiﬁed as having theART (cells/ml) Viral load before ART (copies/ml) Time on ART (years)
60 735 0
13 284 0
23 597 0
47 907 0
70 000 0
9043 0
86 000 0
91 000 0
19 000 0
19 000 0
8192 1
11 000 1
13 000 1
8500 1
12 000 1
10 000 1
6200 1
25 000 1
12 000 1
700 1
27 000 5
34 000 5
37 000 5
21 000 5
11 000 5
15 000 5
190 000 5
22 000 5
2200 5
140 000 5
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conﬁrmed by PCR.46
2.2. Primers, probes, and M13 bacteriophages containing target
sequences were used as standards for real-time PCR (qPCR)
The primer and probe sequences for the qPCR assays were
optimized and designed to be as similar as possible to both
previous reports.47,48 The chemokine receptor CCR5 was chosen as
a surrogate for estimating the number of cells, because each cell
contains only a single copy of CCR5, as shown previously.49,4
2.3. qPCR quantiﬁcation of HIV-1 DNA and cellular CCR5
Total DNA from the target cells was extracted using the QIAamp
DNA Blood Mini Kit (Qiagen). qPCR was performed in a 25-ml
volume containing 2.5 ml DNA target, 12.5 ml Gene Expression
Master Mix (Applied Biosystems, 4369016), 1 mM primers, and
0.2 mM probe. The reaction consisted of the following conditions
using an ABI 7500 PCR machine (Applied Biosystems): 95 8C for
10 min, followed by 95 8C for 15 s and 60 8C for 1 min (40 cycles). A
single round of qPCR was sufﬁcient for total HIV-1 DNA and the
CCR5 gene using the reaction conditions indicated previously.50
For each run, a standard curve was created in a 7-log-unit range by
1:10 serial dilutions of the M13 bacteriophage standard containing
the appropriate gene; all samples were performed in duplicate.
2.4. Cell isolation
Peripheral blood mononuclear cells (PBMCs) were isolated
using Ficoll–Hypaque density gradient centrifugation of heparin-
ized blood samples. CD4+CD25+CD127 Treg cells were isolated
from PBMCs by CD4 negative selection followed ﬁrst by CD127
negative selection and then by CD25 positive selection using a
CD4+CD25+CD127dim/ isolation kit (Miltenyi Biotech) with
MidiMACS and MiniMACS separator units (Miltenyi Biotech),
according to the manufacturer’s instructions. The purity of
CD4+CD25+CD127dim/ Treg cells was >90% for each subject
group, as determined by ﬂow cytometry analysis (Figure 1a).
2.5. Cell culture
PBMCs (1  106), PBMCs depleted of Treg cells (1  106), and
Treg cells (2.5  105) were maintained in RPMI 1640 medium
(Gibco, Grand Island, NY, USA) supplemented with 10% heat-
inactivated human AB serum, 2 mM L-glutamine, 20 mM HEPES,
100 U/ml penicillin, 100 g/ml streptomycin, and 5  105 M
2-mercaptoethanol. After incubation at 37 8C in a 5% CO2
atmosphere for 72 h, the cells were washed, stained, and analyzed.Figure 1. HIV-DNA levels are higher in Treg cells than in non-Treg CD4+ cells. (a) Dot plot
(b) Comparison of HIV-DNA levels (per 106 cells) between Treg and non-Treg CD4+ ce2.6. Flow cytometry analysis
All antibodies were purchased from BD Pharmingen (San Diego,
CA, USA), except anti-HIV-1 gag p24 KC57-FITC, which was from
Beckman Coulter (Fullerton, CA, USA), and phycoerythrin (PE)-
labeled HLA-A2 pentamer complexes loaded with the HIV-1 gag
p17 epitope (77–85, SL9, SLYNTVATL), which were from ProIm-
mune (Oxford, UK). PBMCs were isolated from freshly heparinized
blood by Ficoll–Hypaque centrifugation (Pharmacia, Uppsala,
Sweden).
After 72 h of cell culture, the detection of CD4 cell activation
was performed by immunolabeling with PE-anti-HLA-DR, FITC-
anti-CD38, PerCP-anti-CD3, and APC-anti-CD4.
For the staining of virus-speciﬁc CD8+ T cells, the cells
were simultaneously stained after 72 h of culture with anti-
CD3-PerCP, anti-CD8-allophycocyanin, pentamer-PE, or the
corresponding isotype. For the assessment of intracellular p24
gag expression in CD4+ T cells, the cells were harvested
after 72 h of cell culture and were ﬁrst stained with PerCP-
anti-CD3 and APC-anti-CD4, and then ﬁxed and stained using
the Fix and Perm kit (Caltag) and anti-p24 KC7-FITC antibody, as
described previously.51,52 After staining, four-color ﬂow cyto-
metry analyses were performed using a FACSCalibur ﬂow
cytometer and CELLQUEST software (Becton-Dickinson, San
Jose, CA, USA).
2.7. ELISA
Detection of p24 antigens in the cell culture supernatant was
done by ELISA. In brief, 96-well MaxiSorp plates (Nunc, Denmark)
were coated with 0.5 mg/ml of anti-Gag p24 antibodies in 15 mM
Na2CO3, 35 mM NaHCO3 (pH 9.7), overnight at 4 8C. The plates
were blocked in phosphate-buffered saline (PBS) containing 2% (w/
v) skimmed milk, and sera were added in serial dilutions. Speciﬁc
antibodies were detected following incubation with rabbit anti-
human IgG1 or IgG2a conjugated to horseradish peroxidase
(Zymed/Invitrogen). Development and absorbance reading was
done as described above.
2.8. Assays for CD4 T cell counts and plasma HIV-1 RNA levels
T cell counts were determined by three-color ﬂow cytometry
using anti-CD3-APC, anti-CD4-FITC, and anti-CD8-PE monoclonal
antibodies (BD Bioscience San Diego, CA, USA). The analysis was
performed using a BD FACSCount ﬂow cytometer in accordance
with the Chinese Center for Disease Control and Prevention (CDC)
guidelines. Plasma HIV RNA was quantiﬁed by real-time PCR
(Roche, Germany). The detection sensitivity of this assay is
40 copies/ml.s of ﬂow cytometry results obtained for puriﬁed CD4+CD25+CD127 regulatory cells.
lls in treatment-naı¨ve, ART1, and ART5 patients.
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Comparisons were performed using non-parametric indepen-
dent sample tests, and all reported p-values were two-sided and
considered signiﬁcant at p < 0.05. All data were analyzed using
SPSS statistical software, version 16.0 (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. HIV persistence in Treg cells
To determine whether Treg cells are an important site of
HIV persistence, the HIV-DNA levels in Treg and non-TregFigure 2. There is more p24 in Treg cells than in non-Treg cell culture supernatant. (a) R
cells after 72 h of culture. Comparison of p24 levels in PBMC, non-Treg PBMC, and Treg cel
in cell culture supernatant of PBMC, non-Treg PBMC, and Treg cells from (d) ART1 andCD4+ cells from direct material from 30 HIV-infected
patients (10 treatment-naı¨ve, 10 ART1, and 10 ART5 patients)
were examined. The results showed a higher level of HIV-DNA
in Treg cells than in non-Treg CD4+ cells in all three groups
of patients (Figure 1b, p < 0.001), with an approximately
10-fold higher HIV-DNA level in Treg cells than in non-Treg
cells (Figure 1b). Further, the intracellular HIV-1 p24 levels
in PBMCs, PBCMs depleted of Treg cells, and Treg cells after
72 h of cell culture and the levels of p24 antigen in the cell
culture supernatant were examined. It was found that there
were more p24 antigens in Treg cells than in the other cell types
(Figure 2a–c), as well as in Treg cell culture supernatant
(Figure 2d, e).epresentative plots of the percentage of p24 in the PBMC, non-Treg PBMC, and Treg
ls from (b) ART1 and (c) ART5 patients after 72 h of culture. Comparison of p24 levels
 (e) ART5 patients after 72 h of culture. Patients are numbered P11 through P30.
Y.-M. Jiao et al. / International Journal of Infectious Diseases 37 (2015) 42–49463.2. Depletion of Treg cells facilitates CD4+ T cell activation
Because Treg cells can suppress immune activation, whether
the depletion of Treg cells facilitates CD4+ T cell activation after
certain periods of ART was next examined (Figure 3a). The results
indicated that the depletion of Treg cells induced CD4+ T cell
activation in all patients after 72 h of cell culture, regardless of the
treatment period (Figure 3b–d). These results support the notion
that Treg cell depletion facilitates CD4+ T cell activation.
3.3. Depletion of Treg cells increases the frequency of HIV-speciﬁc
CD8+ T cells with prolonged ART
Because depletion of Treg cells in HIV-infected individuals
would induce immune cell activation, whether the depletion of
Treg cells would increase the frequency of HIV-speciﬁc CTL after
different time periods of ART and thereby improve the control of
viral persistence was investigated (Figure 4a). As shown in
Figure 4b, four of the 10 treatment-naive patients exhibited an
elevated frequency of HIV-speciﬁc CTL after depletion of Treg cells,
whereas the other six patients exhibited a reduced frequency of
HIV-speciﬁc CTL after depletion of Treg cells after 72 h of cell
culture. The frequencies of HIV-speciﬁc CTL were elevated in six of
the 10 ART1 patients and all of the ART5 patients upon the
depletion of Treg cells after 72 h of cell culture (Figure 4c, d).
4. Discussion
An increasing body of evidence has demonstrated that Treg
cells can reduce both HIV-speciﬁc immunoreactions29,31 and
immune activation during HIV-1 infection.25,32,33 It has also been
demonstrated that stimulating HIV-1-speciﬁc CTLs and reactivat-
ing latent HIV-1 may be essential for the successful eradication of
the latent viral reservoir.1 Accordingly, it was hypothesized that
the depletion of Treg cells may be beneﬁcial for reducing the HIV-1
DNA levels and decreasing HIV-1 p24 production. In this study, the
results showed that the HIV-DNA levels were approximately 10-
fold higher in Treg cells than in non-Treg CD4+ cells and that theFigure 3. Depletion of Tregs enhances the activation of CD4+ T cells in patients on prolo
Changes in the ratios of the percentages of HLADR+CD38+ T cells over total CD4+ cell c
treatment-naı¨ve, (c) ART1, and (d) ART5 patients. The y-axis represents the ratios of the p
numbered P1 through P30.depletion of Treg cells increased CD4+ cell activation after 5 years
of ART. Because HIV should exist primarily as a latent viral
reservoir after 5 years of sustained viral response to ART, these
ﬁndings of higher levels of p24 antigen in Treg cells and in Treg cell
culture supernatants indicate that Treg cell depletion may reduce
the viral reservoir. Therefore, Treg cell depletion may facilitate the
elimination of latent HIV by reducing the viral reservoir and
elevating the frequency of HIV-speciﬁc CD8+ T cells. Although the
results of the present study demonstrate that Treg cells can
increase the level of CD4+ cell activation, these data do not indicate
that Treg cell depletion can reactivate latent virus. Further studies
should be performed to conﬁrm whether Treg cell depletion can
reactivate latent virus.
In addition, it has become increasingly clear that the severity of
AIDS is associated with chronic immune hyperactivation. Because
the immune activation was high in the non-ART and ART1 patients,
the depletion of Treg cells may have caused an enhancement of this
excessive immune activation.25 However, in the 5-year ART
patients, HIV had been suppressed for a very long time, and the
excessive immune activation had been controlled to some extent.
These results are consistent with those of previous reports that
have shown that a low Treg response may contribute to both viral
control and generalized immune activation in HIV controllers.35–
37,53 Treg cells are Foxp3-positive cells. Bettelli et al. initially
described Foxp3 as functionally interacting with and inhibiting the
transactivation of the transcription factors nuclear factor of
activated T cells (NFAT) and nuclear factor kappa B (NF-kB).54
Several groups have reported changes in the histone acetylation of
certain promoters regulated by Foxp3.38,55,56 Thus, the mechanism
by which Treg cell depletion could reactivate latent HIV needs
further study.
In this study, it was found that the depletion of Treg cells
elevated the frequency of HIV-1-speciﬁc CTL, which is consistent
with previous publications. A notable report showed that HIV-
speciﬁc CD8+ T cells carrying protective HLA alleles (HLA B*27 and
B*57) were able to evade Treg suppression,57 which suggested that
the suppressive activity of Treg cells may be a major mechanism
that impairs the development of protective effector responses. Itnged ART. (a) Representative plots of CD38 and HLA-DR expression in CD4+ T cells.
ounts in PBMCs (dots on the left) and depleted Treg cells (dots on the right) in (b)
ercentage of HLADR+CD38+ T cells over the total CD4+ cell counts. The patients are
Figure 4. Depletion of Treg cells increases the frequency of HIV-speciﬁc CD8+ T cells in patients on prolonged ART. (a) Representative plots of HIV-speciﬁc CD8+ T cells.
Changes in the ratios of the percentages of HIV-speciﬁc CD8+ T cells over total CD8+ cell counts in PBMCs (dots on the left) and depleted Treg cells (dots on the right) in (b)
treatment-naı¨ve, (c) ART1, and (d) ART5 patients. The y-axis represents the ratios of the percentage of HIV-speciﬁc CD8+ T cells over total CD8+ cell counts. The patients are
numbered P1 through P30.
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associated with non-progressive disease.58 Other reports have
shown the ex vivo depletion of Tregs from PBMCs or lymphoid cell
suspensions to enhance T cell responses to HIV or SIV anti-
gens.29,30,58–62 Furthermore, the stimulation of HIV-1-speciﬁc CTLs
and the reactivation of latent HIV-1 may be essential for the
successful eradication of the latent viral reservoir.1 In this study, it
was found that Treg cells are important HIV-1 p24-producing cells
and the depletion of Treg cells may increase the frequency of HIV-
1-speciﬁc CTLs and reactivate CD4+ cells, thereby enhancing the
eradication of the latent viral reservoir. In addition, because onlythe HLA-A2-positive phenotype can be detected by ﬂow cytome-
try, cells from HLA-A2-positive phenotype patients were examined
by ﬂow cytometry and the CTL detected; however, this does not
exclude the possibility that individuals with other HLA phenotypes
respond in the same way.
It was found that the HIV-DNA levels were higher in Treg cells
than in non-Treg CD4+ cells, which is consistent with the report
that HIV-DNA-harboring cells appeared to be more abundant in the
Treg subset than among non-Treg cells in patients on prolonged
ART.44 It was found that the HIV-DNA levels were 10-fold higher in
Treg cells than in non-Treg CD4+ cells; in a previous report, this
Y.-M. Jiao et al. / International Journal of Infectious Diseases 37 (2015) 42–4948difference ranged from 1.5- to 8-fold higher.44 This variation may
be due to racial differences and the different surface markers used.
Because the results of the present study, along with those reported
in a number of previous publications, suggest that Treg cells could
constitute part of the viral reservoir, the depletion of Treg cells may
reduce the size of this viral reservoir.
The latent reservoir is established at the earliest stage of
infection. Furthermore, ART in acutely infected macaques
increases SIV-speciﬁc viral responses and the capacity of the
immune response.63 The transient depletion of Treg cells in
transgenic mice reactivated virus-speciﬁc CD8+ T cells and reduced
the retroviral set points.64 Thus, early ART in combination with
Treg cell depletion may help preserve immune responses and
eliminate the viral reservoir; however, this hypothesis requires
further study for conﬁrmation.
In conclusion, CD4+CD25+CD127 regulatory cells play multiple
roles in maintaining HIV-1 p24 production in long-term ART
patients. The results of this study indicate that the depletion of
Treg cells may facilitate the elimination of HIV-1 p24 production
by depleting those cells that produce p24 and by increasing the
frequency of HIV-speciﬁc CD8+ T cells. Whether Treg cell depletion
can reactivate latent virus needs further examination. Indeed, Treg
cells may be a good target for strategies to eliminate the latent HIV
reservoir.
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